Inotiv, Inc. (NOTV)
| Market Cap | 48.57M |
| Revenue (ttm) | 552.74M |
| Net Income (ttm) | -71.29M |
| Shares Out | 25.97M |
| EPS (ttm) | -2.77 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 297,111 |
| Open | 1.930 |
| Previous Close | 1.930 |
| Day's Range | 1.860 - 1.930 |
| 52-Week Range | 1.610 - 11.420 |
| Beta | 3.38 |
| Analysts | Buy |
| Price Target | 6.19 (+231.02%) |
| Earnings Date | May 15, 2024 |
About NOTV
Inotiv, Inc. provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries. It operates through two segment: Discovery and Safety Assessment (DSA), and Research Models and Services (RMS). The DMS segment manufactured scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the Company's BASi product line. The RMS segment engages in commercial p... [Read more]
Financial Performance
In 2023, Inotiv's revenue was $572.43 million, an increase of 4.52% compared to the previous year's $547.66 million. Losses were -$105.14 million, -68.80% less than in 2022.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for NOTV stock is "Buy." The 12-month stock price forecast is $6.19, which is an increase of 231.02% from the latest price.
News
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Inotiv, Inc. (NOTV)
NEW YORK--(BUSINESS WIRE)-- #Investigation--The law firm of Kirby McInerney LLP is investigating potential claims against Inotiv, Inc. (“Inotiv” or the “Company”) (NASDAQ: NOTV). The investigation con...
Inotiv Reports Second Quarter Financial Results for Fiscal 2024 and Provides Business Update
— Second quarter fiscal 2024 revenue down 21.5% to $119.0 million— Year-to-date fiscal 2024 revenue down 7.2% to $254.5 million— Agreement in principle reached with the U.S. Department of Justice on r...
Inotiv, Inc. to Report Fiscal 2024 Second Quarter Financial Results and Host Conference Call on Wednesday, May 15, 2024
WEST LAFAYETTE, Ind., May 14, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical dru...
Inotiv, Inc. Reschedules its Fiscal 2024 Second Quarter Results
WEST LAFAYETTE, Ind., May 09, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization specializing in nonclinical and analytical drug discovery a...
INOTIV INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Inotiv, Inc. - NOTV
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigat...
Inotiv, Inc. to Report Fiscal 2024 Second Quarter Financial Results and Host Conference Call on Friday, May 10, 2024
WEST LAFAYETTE, Ind., April 29, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical d...
INOTIV INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Inotiv, Inc. - NOTV
NEW ORLEANS, La. , April 19, 2024 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C.
Inotiv Reports First Quarter Financial Results for Fiscal 2024 and Provides Business Update
- First quarter fiscal 2024 revenue up 10.3% to $135.5 million - First quarter fiscal 2024 DSA revenue up 8.8% to $44.7 million and RMS revenue up 11.1% to $90.8 million - Shift to a renewed focus on ...
Inotiv, Inc. to Report Fiscal 2024 First Quarter Financial Results and Host Conference Call on Wednesday, February 7, 2024
WEST LAFAYETTE, Ind., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical dr...
INOTIV ALERT: Bragar Eagel & Squire, P.C. is Investigating Inotiv, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NEW YORK--(BUSINESS WIRE)-- #A--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Inotiv, Inc. (NASDAQ: NOTV) on behalf of lon...
Inotiv Reports Fourth Quarter and Full Year Financial Results for Fiscal 2023 and Provides Business Update
— Fiscal year 2023 revenue up 4.5% to $572.4 million, achieving full year revised guidance— Achievements in the past fiscal year to expand DSA capacity, develop new services and reduce outsourcing exp...
Inotiv, Inc. Announces Plan to Insource North American Transportation Operations
WEST LAFAYETTE, Ind., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization specializing in nonclinical and analytical drug discovery ...
Inotiv, Inc. to Report Fiscal 2023 Fourth Quarter and Full Year Results and Host Conference Call on Monday, December 11, 2023
WEST LAFAYETTE, Ind., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and a...
Inotiv Provides Business Updates and Upcoming Investor Conferences Update
WEST LAFAYETTE, Ind., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV), a leading contract research organization specializing in nonclinical and analytical drug discovery and development ...
Inotiv Ranked Number 127 Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500™
Attributes 1156% Revenue Growth to Adding Strategic Capacity, Key Integration Initiatives, Optimization of Infrastructure, and Right-Sizing its Global Footprint Attributes 1156% Revenue Growth to Addi...
Inotiv, Inc. to Participate in Upcoming Investor Conferences
WEST LAFAYETTE, Ind., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV), a leading contract research organization specializing in nonclinical and analytical drug discovery and development ...
Inotiv, Inc. Announces Changes to its Board Composition
WEST LAFAYETTE, Ind., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV), a leading contract research organization, today announced the appointment of Terry Coelho to its Board of Directors...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Inotiv, Inc. - NOTV
NEW YORK , Oct. 9, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Inotiv, Inc. ("Xylem" or the "Company") (NASDAQ: NOTV). Such investors are advised to contact Ro...
Inotiv Announces the Sale of its Israeli Businesses to Harlan Holdings Ltd.
WEST LAFAYETTE, Ind., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and a...
Inotiv, Inc. to Participate in Upcoming September 2023 Investor Conferences
WEST LAFAYETTE, Ind., Aug. 24, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and a...
Inotiv, Inc. (NOTV) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
NEW YORK , Aug. 15, 2023 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Inotiv, Inc. ("Inotiv" or "the Company"...
Inotiv Reports Third Quarter Financial Results for Fiscal 2023 and Provides Business Update
WEST LAFAYETTE, Ind., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and a...
Inotiv, Inc. to Report Fiscal 2023 Third Quarter Financial Results and Host Conference Call on Thursday, August 10, 2023
WEST LAFAYETTE, Ind., July 24, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and a...
Inotiv, Inc. to Present at Jefferies 2023 Healthcare Conference
WEST LAFAYETTE, Ind., May 25, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and an...
Inotiv, Inc. to Participate in May Investor Conferences
WEST LAFAYETTE, Ind., May 19, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and an...